Oramed Pharmaceuticals (ORMP) Current Assets (2011 - 2026)

Oramed Pharmaceuticals has reported Current Assets for 16 years, with the latest figure at $68.1 million in Q1 2026.

• For the quarter ending Q1 2026, Current Assets fell 48.17% year-over-year to $68.1 million; the trailing twelve-month figure through Mar 2026 stood at $68.1 million (down 48.17% YoY), and the FY2025 full-year result was $133.3 million, down 6.95% from the prior year.
• Current Assets for Q1 2026 stood at $68.1 million, down from $133.3 million in the prior quarter.
• The five-year high for Current Assets was $177.1 million in Q1 2024, with the low at $68.1 million in Q1 2026.
• Historically, Current Assets has averaged $142.6 million across 5 years, with a median of $143.6 million in 2022.
• Annual changes were most pronounced in 2024 — Current Assets increased 14.14% — and 2026, when it tumbled 48.17%.
• Oramed Pharmaceuticals' Current Assets stood at $157.1 million in 2022, then gained by 3.48% to $162.6 million in 2023, then fell by 11.91% to $143.2 million in 2024, then dropped by 6.95% to $133.3 million in 2025, then slumped by 48.86% to $68.1 million in 2026.
• The last three Current Assets figures came in at $68.1 million (Q1 2026), $133.3 million (Q4 2025), and $136.1 million (Q3 2025), per Business Quant data.